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Aims The aim of this study is to compare the effects of a 24 h intravenous infusion of levosimendan and a 48 h infusion of
dobutamine on invasive haemodynamics in patients with acutely decompensated chronic NYHA class III–IV heart
failure. All patients were receiving optimal oral therapy including a b-blocker.
Methods
and results
This was a multinational, randomized, double-blind, phase IV study in 60 patients; follow-up was 1 month. There was a
signiﬁcant increase in cardiac index and a signiﬁcant decrease in pulmonary capillary wedge pressure (PCWP) at 24
and 48 h for both dobutamine and levosimendan. The improvement in cardiac index with levosimendan was not sig-
niﬁcantly different from dobutamine at 24 h (P ¼ 0.07), but became signiﬁcant at 48 h (0.44+0.56 vs. 0.66+0.63 L/
min/m
2; P ¼ 0.04). At 24 h, the reduction in the mean change in PCWP from baseline was similar for levosimendan
and dobutamine, however, at 48 h the difference was more marked for levosimendan (23.6+7.6 vs.
28.3+6.7 mmHg; P ¼ 0.02). No difference was observed between the groups for change in NYHA class,
b-blocker use, hospitalizations, treatment discontinuations or rescue medication use. Reduction in B-type natriuretic
peptide (BNP) was signiﬁcantly greater with levosimendan at 48 h (P ¼ 0.03). According to physician’s assessment,
the improvement in fatigue (P ¼ 0.01) and dyspnoea (P ¼ 0.04) was in favour of dobutamine treatment, and hypo-
tension was signiﬁcantly more frequent with levosimendan (P ¼ 0.007). No increase in atrial ﬁbrillation or ventricular
tachycardia was seen in either group.
Conclusion A 24 h levosimendan infusion achieved haemodynamic and neurohormonal improvement that was at least compar-
able at 24 h and superior at 48 h to a 48 h dobutamine infusion.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Despite optimal oral therapy, patients with acutely decompensated
heart failure (ADHF) may experience periods of decompensation
that require short-term therapy with positive inotropic agents.
These agents may increase myocardial oxygen consumption and
worsen myocardial ischaemia and, while they may improve pump
function acutely and stabilize the patient’s condition, there may
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doi:10.1093/eurjhf/hfq032be an increased frequency of arrhythmias and death. Whether this
is also the case in patients with ADHF treated with optimal
dosages of b-blockers remains unclear.
Intravenous levosimendan is a novel agent developed for the
short-term treatment of worsening heart failure (HF). It has
been found to increase myocardial contractility via a sensitization
of cardiac troponin C to calcium,
1 and to produce vasodilatation
by opening the ATP-sensitive potassium channels in vascular
smooth muscle cells. Levosimendan also has phosphodiesterase
type III inhibitory properties at high concentrations.
2 Levosimen-
dan induces haemodynamic improvement without an increase in
myocardial oxygen consumption.
3 In randomized, double-blinded
studies in patients with ADHF, intravenous levosimendan adminis-
tered over 6–24 h has been shown to decrease pulmonary capil-
lary wedge pressure (PCWP) and increase cardiac output,
compared both with placebo and dobutamine.
4–6 Moreover, in a
retrospective analysis of the LIDO trial, the haemodynamic advan-
tage of levosimendan over dobutamine was accentuated in the
presence of b-blockers.
6 In the SURVIVE trial, levosimendan and
dobutamine had similar outcome effects,
7 but post hoc analyses
showed that in patients receiving concomitant b-blockers, mor-
tality was lower for levosimendan than dobutamine.
8
Levosimendan may therefore offer an important alternative for
the treatment of ADHF in patients on optimal conventional treat-
ment including a b-blocker and in need of inotropic support.
Because of an active long-acting metabolite (OR-1896),
9,10 the
haemodynamic effects of levosimendan continue for several days
after stopping the infusion. The aim of the present study was to
compare the effects of a 24 h intravenous infusion of levosimendan
with a 48 h infusion of dobutamine on invasive haemodynamics in
patients with ADHF on optimal therapy including a b-blocker. This
was the BEAT-CHF (efﬁcacy and safety of short-term intravenous
treatment with levosimendan vs. dobutamine in decompensated
HF patients treated with beta-blockers) trial.
Methods
The investigation conforms to the principles outlined in the Declara-
tion of Helsinki
11 and the principles of Good Clinical Practice within
the European Union. The protocol and its amendments were
approved by the local ethics committees at each centre. All patients
provided written informed consent before the performance of any
study procedures.
Study population
Sixty patients (29 on levosimendan and 31 on dobutamine) aged over
18 years with ADHF of ischaemic or non-ischaemic origin, in
New York Heart Association (NYHA) class III–IV, despite optimized
conventional treatment for HF including a b-blocker, who had been
on a stable regimen for  3 months at an optimal dosage (in the inves-
tigator’s opinion) and who might beneﬁt from intravenous positive ino-
tropic agents, were enrolled in 13 centres in Sweden, Norway and
Iceland. Patients were required to have a left ventricular ejection frac-
tion (LVEF)   35% within 3 months prior to inclusion, a cardiac
index , 2.5 L/min/m
2, and PCWP . 15 mmHg.
The main exclusion criteria were signiﬁcant mechanical obstruction
affecting ventricular ﬁlling and/or outﬂow, systolic blood pressure
(SBP)   85 mmHg, heart rate   130 b.p.m. persistent for at least
5 min and serum potassium ,3.5 mmol/L or .5.4 mmol/L (or,
alternatively, plasma potassium ,3.4 mmol/L or .4.9 mmol/L) at
screening, or severe angina pectoris during the 6 h before baseline.
Study design
This was a multinational, double-blinded, double-dummy, parallel
group phase IV study. The study consisted of a screening period of
up to 24 h before initiation of treatment, a study drug infusion
period of 48 h, and a follow-up period of 1 month. Patients were hos-
pitalized at a minimum for the duration of the intravenous infusion.
Randomization was stratiﬁed with respect to treatment with carvedilol,
as a subgroup analysis from the LIDO trial
6 suggested that carvedilol
has a different haemodynamic interaction with dobutamine when com-
pared with other b-blockers.
12 Patients within each stratum were ran-
domly allocated to a 24 h infusion with levosimendan or a 48 h infusion
with dobutamine in a 1:1 ratio. All patients received two infusions:
active treatment and a placebo for the alternative treatment.
Study medication
Levosimendan or placebo for levosimendan (Orion Pharma, Espoo,
Finland) was administered as an initial loading dose of 12 mg/kg deliv-
ered over 10 min followed by a continuous infusion of 0.1 mg/kg/min
for 50 min. The infusion rate was increased to 0.2 mg/kg/min for a
further 23 h. If dose-limiting events (DLEs) occurred (as described
below) during administration of the loading dose, the loading dose
was stopped. Upon resolution, the infusion could be restarted at
0.1 mg/kg/min and increased to 0.2 mg/kg/min or reduced to 0.05 mg/
kg/min as appropriate. If DLEs occurred during the infusion, the
dosage could be reduced to 0.1 or 0.05 mg/kg/min.
Dobutamine (Eli-Lilly, Solna, Sweden) or placebo for dobutamine
(Orion Pharma, Espoo, Finland) was given as a continuous infusion
without a loading dose, starting at a rate of 5 mg/kg/min for 1 h, and
increased to 10 mg/kg/min for a further 47 h, unless the dosage was
not tolerated during the ﬁrst 60 min. If DLEs occurred during the infu-
sion, the dosage could be reduced to 5 or 2.5 mg/kg/min.
The optimal dosage of b-blocker administered at baseline was, as far
as possible, to be maintained throughout the study. If possible, diuretic
treatment regimens were to remain constant.
DLEs were deﬁned as symptomatic hypotension, heart rate  
140 b.p.m. constantly over 5 min, development of angina pectoris,
electrocardiographic signs of signiﬁcant myocardial ischaemia, or suspi-
cion of myocardial infarction, development of new malignant tachyar-
rhythmia, or excessive diuresis that was sustained despite reducing the
dosage or discontinuing administration of diuretics. Hypotension was
deﬁned as ‘asymptomatic’ if systolic BP was  75mmHg but the
patient had no symptoms, or ‘symptomatic’ if the patient had symp-
toms attributable to low BP in the opinion of the investigator irrespec-
tive of the blood pressure measurement. In all cases hypotension was
conﬁrmed by a second reading.
In case of worsening of ADHF, the infusion rates were to be adjusted
and/or rescue treatment (e.g. dopamine or epinephrine) administered.
The infusions of both study drugs were to be discontinued perma-
nently if the patient experienced a major cardiovascular event or
serious adverse event (AE).
Efﬁcacy and safety assessments
Haemodynamic variables were measured at baseline and at 0.5, 2, 24,
and 48 h after the start of the infusion using a Swan-Ganz catheter via
central access. Measurements included PCWP and mean right atrial
pressure (mRAP). Arterial blood pressure was measured via an arterial
catheter. Systemic vascular resistance and pulmonary vascular resist-
ance were calculated from the measured parameters. Cardiac index
was calculated from cardiac output, which was measured using the
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oxygen saturation (SvO2) was measured by analysis of blood gases.
NYHA class was assessed at baseline, 48 h after the start of infusion,
and at 1-month follow-up. HF symptoms (dyspnoea and fatigue) were
assessed by both the patients and investigators using a 7-point scale of
responses from markedly improved to markedly worse, at 48 h after
the start of the infusion and at 1-month follow-up.
Changes in b-blocker therapy during the study and the need for
rescue medication or other interventions were documented. Timing,
duration, and the primary reason for admission for hospitalizations
occurring after discharge from the initial hospitalization to the
1-month follow-up were documented and used to calculate days
alive and out of hospital.
B-type natriuretic peptide (BNP) plasma levels were analysed by
radioimmunoassay at a central laboratory from samples collected at
baseline, 24, and 48 h after the start of the infusion and at 1-month
follow-up.
Safety was followed by repeated heart rate and blood pressure
measurements, AE inquiries, ECG assessments, and laboratory
variables.
Statistical methods
Sample size estimation was done using nQuery Advisorw 4.0 (Statisti-
cal Solutions, Saugus, MA, USA). With a sample size of 27 in each
group there was 80% power to detect a 0.75 L/min difference
between treatment groups in change in mean cardiac output at two-
sided 5% signiﬁcance level. Calculation assumed common standard
deviation (SD) of 0.95 L/min. The planned sample size in this phase
IV study was originally 110 patients; however, owing to slow recruit-
ment and on the recommendation of the steering committee, this
was reduced to 60 patients (30 patients per treatment group).
The primary objective was to describe the changes, from baseline to
24 h after the start of study drug infusion, in cardiac index, and PCWP
and to compare the changes between the treatment groups. With the
Hochberg method, signiﬁcance could be declared for both of the
primary haemodynamic variables if both had two-sided P   0.050.
13
Signiﬁcance could also be declared for one of the primary haemo-
dynamic variables if two-sided P   0.025 was reached for one of the
variables and P . 0.05 for the other variable. The intention-to-treat
(ITT) population, comprising all randomized patients who received
study medication, was used in all efﬁcacy analyses.
Changes in both of the haemodynamic variables of the primary
analysis were compared between treatment groups using analysis of
variance (ANOVA) with effects for treatment, use of carvedilol at
baseline and treatment-by-usage of carvedilol interaction (i.e. using
an adjusted model) or the non-parametric Mann–Whitney (M-W)
depending on whether the data were normally distributed. Analyses
were repeated using an unadjusted model. With the exceptions
listed below, secondary variables were described and analysed in the
same way as the primary efﬁcacy variable.
The changes in NYHA class from baseline to the 1-month follow-up
visit were analysed using odds ratio and 95% conﬁdence intervals (95%
CIs). The change in patients’ and investigators’ assessment of fatigue
and dyspnoea were compared between groups using the
Cochran-Mantel-Haenszel row-mean score test. The proportion of
patients with treatment discontinuations and/or need for rescue
therapy owing to lack of efﬁcacy at any time point were analysed
using risk-ratio and 95% CIs.
For the most frequently reported AEs, the incidence was compared
between groups using the x
2 test. All statistical analyses were per-
formed using SASw 9.1.3 (SAS Institute, Cary, NC, USA).
Results
Patient disposition and baseline
characteristics
Patient enrolment was from November 2002 until April 2005.
Sixty patients were randomized and patient disposition is summar-
ized in Figure 1. Demographic and baseline HF characteristics were
similar in both treatment groups (Table 1).
Figure 1 Patient disposition.
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Table 1 Patient characteristics at baseline
(ITT population)
Characteristic Levosimendan
(n 5 29)
Dobutamine
(n 5 31)
Age (years), mean (SD) 70 (10) 71 (11)
Sex male, n (%) 26 (90) 25 (81)
BMI (kg/m
2), mean (SD) 27.0 (5.4) 25.7 (4.0)
Ethnic origin, n (%)
Asian 0 (0) 1 (3)
Caucasian 29 (100) 27 (87)
Hispanic 0 (0) 1 (3)
Other 0 (0) 2 (7)
NYHA class, n (%)
III 17 (59) 16 (52)
IV 12 (41) 15 (48)
Primary aetiology, n (%)
Ischaemic 22 (76) 18 (58)
Non-ischaemic 5 (17) 11 (36)
Other 2 (7) 2 (7)
EF (%), mean (SD) 21.2 (5.8) 21.8 (6.1)
BMI, body mass index; EF, ejection fraction; NYHA, New York Heart Association;
ITT, intention-to-treat.
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patients and 94% of dobutamine patients) achieved the target
dosage within 2 h of starting the infusion. The mean continuous
infusion rate administered and the duration of infusion were
0.19 mg/kg/min (SD 0.03) and 22.8 h (SD 4.4) for levosimendan
and 10.1 mg/kg/min (SD 0.41) and 46.6 h (SD 7.9) for dobutamine.
In total, 25 (86.2%) levosimendan patients and 27 (87.1%) dobuta-
mine patients underwent the 1-month follow-up visit.
Efﬁcacy
Haemodynamic assessments
Both levosimendan and dobutamine infusions induced haemo-
dynamic improvement (Figure 2). At 24 h, the mean improvement
in cardiac index from baseline showed a trend in favour of levosi-
mendan over dobutamine (M-W P ¼ 0.066). At 48 h, the differ-
ence between groups was statistically signiﬁcant (M-W P ¼ 0.037).
At 24 h, the reduction in the mean change in PCWP from base-
line was similar for levosimendan and dobutamine (ANOVA P ¼
0.105) (Table 2). At 48 h, the difference between the groups in
the mean change in PCWP from baseline was more marked for
levosimendan than for dobutamine (ANOVA P ¼ 0.015) (Figure 2).
Changes in other haemodynamic variables were generally con-
sistent with the ﬁndings for the co-primary analyses (Table 2).
There was no marked difference between the groups for the
change in mRAP or SvO2 from baseline.
Symptomatic improvement, hospitalizations,
and concomitant medications
There was no difference between the groups in the change in
NYHA class from baseline at 48 h and at 1-month follow-up.
The patients reported similar improvements in HF symptoms at
24 and 48 h in the levosimendan and dobutamine groups. Accord-
ing to the investigators’ assessments of both fatigue and dyspnoea,
the differences between the groups at 24 h were statistically signiﬁ-
cant; 93% of patients in the dobutamine group vs. 62% in the levo-
simendan group were reported to have improvement in fatigue
(P ¼ 0.010), and 87% vs. 76%, respectively, in dyspnoea (P ¼ 0.038).
The differences between the groups were less marked at 48 h.
There were no signiﬁcant differences between groups in terms
of b-blocker use at follow-up, days alive and out of hospital, and
treatment discontinuations and rescue medications required
owing to lack of efﬁcacy. The mean percentage change in the
dose of b-blockers from screening until the 1-month follow-up
visit was 9.5% (SD 38.0) for the levosimendan group, and 21.5%
(SD 128.0) for the dobutamine group (P ¼ 0.283). Fourteen
patients were rehospitalized (six levosimendan patients; eight
dobutamine patients) and the mean number of days alive and
out of hospital during the 30 days following the start of study
drug infusions was similar in both treatment groups. No levosimen-
dan patients and two dobutamine patients required rescue medi-
cation (including intravenous levosimendan, dobutamine, and
crystalloids). Two levosimendan patients discontinued because of
lack of efﬁcacy compared with one dobutamine patient. The
requirement for rescue medication or discontinuation owing to
lack of efﬁcacy was not statistically different between the two
groups at 1-month follow-up (odds ratio 0.73, 95% CI 0.11, 4.92;
P ¼ 0.76, CMH test stratiﬁed for carvedilol use).
B-type natriuretic peptide
The reductions in BNP from baseline were more marked with
levosimendan than with dobutamine, the difference being statisti-
cally signiﬁcant at 48 h (P ¼ 0.03) (Table 3).
Safety
Thirteen DLEs were reported for nine (31.0%) levosimendan
patients and ﬁve DLEs for four (12.9%) dobutamine patients
(P ¼ 0.09).
The AE proﬁles were generally similar in both treatment groups
(Table 4), with the exception of hypotension, which was more fre-
quent in the levosimendan group (35% vs. 7%, respectively; P ¼
0.007) and nausea (P ¼ 0.032). Cardiac arrhythmias were infre-
quent; ventricular tachycardia was reported in one patient from
each group, and atrial ﬁbrillation was reported in one patient
from the levosimendan group. However, it should be noted that
since no Holter recording or such was made during the study,
this may not be entirely accurate.
Consistentwiththemorefrequentreportingofhypotensionasan
AE for levosimendan patients, SBP decreased more during the infu-
sion of levosimendan than dobutamine (Figure 3). The differences
between groups in mean change in SBP from baseline were statisti-
cally signiﬁcant at 0.5, 2, and 24 h, but not at 48 h (Figure 3).
Heart rate gradually increased after administration of levosimen-
dan from 72 b.p.m. at baseline to 80 b.p.m. at 48 h. In the
Figure 2 Mean cardiac index and pulmonary capillary wedge
pressure from baseline to 48 h after the start of the study drug
infusion [intention-to-treat (ITT) population].
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(84 b.p.m.), and decreased to 79 b.p.m. at 48 h. The difference at
48 h was not statistically signiﬁcant.
Two patients died during the study (one levosimendan, one
dobutamine) and one patient (levosimendan group) died three
days after discontinuing the study.
There were no signiﬁcant differences in any of the laboratory
variables measured.
Discussion
The primary objective of this study was to demonstrate a signiﬁ-
cantly greater improvement in PCWP and/or cardiac index at
24 h after the start of the infusion for levosimendan compared
with dobutamine in patients who had NYHA stage III–IV ADHF
despite optimal oral treatment, including a b-blocker. Both treat-
ments induced haemodynamic improvement in these patients.
Even though the primary objective was not met, a trend in
favour of levosimendan was seen at 24 h after the start of study
drug infusion. This was consistent with previous ﬁndings in the
LIDO study, where levosimendan showed a signiﬁcantly greater
decrease in PCWP and a signiﬁcantly greater increase in cardiac
output.
6 Further, this difference became signiﬁcant at 48 h, even
though levosimendan was only administered for 24 h and dobuta-
mine for 48 h. Two factors, the concomitant b-blockade diminish-
ing effect on dobutamine and the formation of an active metabolite
of levosimendan, probably account for these ﬁndings.
Although pharmacokinetic parameters were not measured in
the present study, previous studies have shown that levosimendan
has an active metabolite (OR-1896), which has a considerably
...............................................................................................................................................................................
Table 2 Haemodynamic values at baseline and change from baseline to 24 and 48 h (ITT population)
Time point Levosimendan (n 5 29) Dobutamine (n 5 31) P-value
a,b
CI (L/min/m
2)
Baseline, mean (SD) 1.78 (0.42) 1.74 (0.40)
24 h mean change (SD) 0.79 (0.56)
‡ 0.53 (0.57)
‡ 0.066
a
48 h mean change (SD) 0.66 (0.63)
‡ 0.44 (0.56)
‡ 0.037
a
PCWP (mmHg)
Baseline, mean (SD) 23.8 (4.8) 23.0 (7.0)
24 h mean change (SD) 25.8 (8.2)
‡ 22.6 (7.9)
NS 0.105
b
48 h mean change (SD) 28.3 (6.7)
‡ 23.6 (7.6)
† 0.015
b
Heart rate (b.p.m.)
Baseline, mean (SD) 71.7 (13.6) 74.6 (13.5)
24 h mean change (SD) 6.5 (13.7)
‡ 3.0 (10.2)
NS 0.267
b
48 h mean change (SD) 8.3 (8.8)
‡ 4.7 (9.8)
† 0.166
b
Stroke volume (mL)
Baseline, mean (SD) 50.50 (15.33) 45.95 (15.13)
24 h mean change (SD) 16.04 (14.42)
‡ 11.57 (15.84)
‡ 0.401
b
48 h mean change (SD) 11.20 (14.46)
‡ 7.22 (13.18)
† 0.660
b
SVR ((dyne   s)/cm
5)
Baseline, mean (SD) 1555 (519) 1742 (416)
24 h mean change (SD) 2590 (435)
‡ 2477 (481)
‡ 0.288
b
48 h mean change (SD) 2525 (408)
‡ 2426 (469)
‡ 0.286
a
PVR ((dyne   s)/cm
5)
Baseline, mean (SD) 274 (146) 348 (210)
24 h mean change (SD) 287 (126)
† 257 (163)
NS 0.652
a
48 h mean change (SD) 271 (152)
NS 254 (149)
NS 0.897
b
mRAP (mmHg)
Baseline, mean (SD) 13.4 (6.6) 12.6 (5.7)
24 h mean change (SD) 23.4 (5.0)
‡ 24.0 (4.8)
‡ 0.732
a
48 h mean change (SD) 23.9 (6.1)
‡ 22.9 (5.5)
† 0.692
a
SvO2 (%)
Baseline, mean (SD) 58 (12) 58 (9)
24 h mean change (SD) 6.9 (13)
‡ 8.1 (7.3)
‡ 0.703
a
48 h mean change (SD) 8.0 (10)
‡ 6.0 (6.4)
‡ 0.417
b
CI cardiac index; PCWP pulmonary capillary wedge pressure; SVR systemic vascular resistance; PVR pulmonary vascular resistance; mRAP mean right arterial pressure; SvO2
mixed venous oxygen saturation; NS, non-signiﬁcant.
Statistical testing is performed between-treatment groups at given time (
aM-W test;
bANOVA) and within-treatment groups as baseline vs. post drug using ANOVA (
†P , 0.05;
‡P , 0.01;
NSP ,  0.05).
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1 h).
9,10 In line with the present ﬁndings, a 24 h levosimendan infu-
sion has previously been shown to maintain the haemodynamic
effects at a similar level at 24 and 48 h,
10 with the effects lasting
for about 7 days.
14 The haemodynamic effects of dobutamine
may diminish owing to tachyphylaxis,
15,16 but in the present
study this was not seen, and cardiac index and PCWP were at
similar levels at 24 and 48 h in the dobutamine group.
The haemodynamic changes observed at 24 h in the b-blocked
patients in the LIDO study showed an improvement in cardiac
index, which was similar in magnitude to the improvement
observed in this study. However, in the LIDO study, the
dobutamine patients did not respond as well as the levosimendan
patients. In contrast, in the present study, cardiac index improved
to a similar extent in both the levosimendan and dobutamine
groups at 24 h. The total dose of dobutamine over the ﬁrst 24 h
of the infusion was somewhat higher in the present study com-
pared with LIDO, so the higher dosage might explain the greater
improvements in the dobutamine group in the present study.
However, a more likely explanation for these minor differences
between the groups is the relatively small number of patients in
both the LIDO subgroup and the present study.
Previous studies with levosimendan have demonstrated a
reduction in plasma BNP concentrations, correlating with improve-
ments in haemodynamic status in ADHF patients.
7 Consistent with
these ﬁndings, BNP levels were lower during levosimendan treat-
ment and the difference between treatments was statistically sig-
niﬁcant at 48 h in the present study.
In both treatment groups, the majority of patients reported
either improved or unchanged HF symptoms (dyspnoea and
fatigue). According to the physician’s assessment, a greater pro-
portion of patients in the dobutamine group were reported to
have an improvement in these symptoms. The pharmacodynamic
proﬁle of dobutamine is consistent with a short-term experience
of improvement. As patients in the study were mostly conﬁned
to bed rest, changes in dyspnoea rating should be interpreted
with caution.
Consistent with the more frequent reporting of hypotension as
an AE for levosimendan patients (35%), SBP decreased more
during the infusion of levosimendan than dobutamine. This is in
contrast to the SURVIVE study, where a similar proportion of
patients experienced hypotension as an AE (16% for levosimendan
and 14% for dobutamine). Generally, the tolerability of levosimen-
dan and dobutamine were similar and mortality rates were low in
both groups.
In the present study, mean heart rate increased with both levo-
simendan and dobutamine (8 and 5 b.p.m. at 48 h, respectively),
with the highest heart rate observed during dobutamine infusion
at 2 h, similar results were reported in the LIDO and SURVIVE
studies.
.........................................................
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Table 4 Incidence of adverse events (>2 subjects) from
the start of study drug infusion to the 1-month follow-up
visit (ITT population)
Event Number (%) of subjects
Levosimendan
(n 5 29)
Dobutamine
(n 5 31)
P-value
a
Total subjects
with at least 1
AE
22 (75.9) 21 (67.7)
Hypotension 10 (34.5) 2 (6.5) 0.007
Insomnia 4 (13.8) 3 (9.7) 0.620
Nausea 4 (13.8) 0 (0.0) 0.032
Cardiac failure 3 (10.3) 4 (12.9) 0.758
Headache 3 (10.3) 1 (3.2) 0.269
Urinary tract
infection
3 (10.3) 1 (3.2) 0.269
Hypokalaemia 1 (3.4) 2 (6.5) 0.594
Cough 1 (3.4) 2 (6.5) 0.594
ax
2 test, where the incidence was more than two subjects in at least one treatment
group.
Figure 3 Mean change from baseline in systolic blood pressure
at baseline and at 0.5, 2, 24, and 48 h after start of the study drug
infusion (ITT population).
................................................................................
Table 3 B-type natriuretic peptide values (ng/mL) at
baseline, change from baseline to 24, and 48 h after the
start of the infusion, and at the 1-month follow-up
(ITT population)
Time point Levosimendan
(n 5 29)
Dobutamine
(n 5 31)
P-value
a
BNP (ng/mL)
Baseline,
mean (SD)
1114 (1214) 979 (748)
24 h mean
change (SD)
2432 (727) 2324 (533) 0.248
48 h mean
change (SD)
2507 (785) 2260 (475) 0.029
1 month
mean
change (SD)
2206 (1094) 52 (471) 0.138
aANOVA.
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Because of slow recruitment, the study was terminated before the
prespeciﬁed number of patients had been included, which wea-
kened the scientiﬁc conclusions of the study. The two study
drugs, levosimendan and dobutamine have different pharmacoki-
netic and pharmacodynamic proﬁles, resulting in a different dur-
ation of effect. This was compensated for by administering the
two drugs for different lengths of time, but it is possible that the
duration of effect may still have been different.
Conclusions
In conclusion, in HF patients experiencing acute decompensation
while receiving optimal b-blocker therapy, a 24 h levosimendan
infusion achieved haemodynamic and neurohormonal improve-
ment that lasted beyond the infusion period. The improvement
with levosimendan was at least comparable to a 48 h dobutamine
infusion at 24 h after the start of the infusion and superior at 48 h.
This lasting effect is corroborated by clinical observations indicat-
ing a practical advantage over dobutamine.
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